Overview


According to FutureWise analysis the market for Acquired Aplastic Anemia is expected to reach US$ 10.65 billion by 2031 at a CAGR of 4.42%.

Acquired aplastic anemia is a medical condition that is rare and can be fatal. It occurs when the bone marrow fails to produce enough new blood cells. The destruction of the bone marrow leads to a significant decrease in the production of white blood cells, red blood cells, and platelets. Complications of acquired aplastic anemia include exhaustion, recurrent infections, bleeding, and a higher chance of contracting other serious diseases. Restoring and enhancing the generation of blood cells is the main objective of treatment for acquired aplastic anemia. Bone marrow transplants, immunosuppressive therapy, and blood transfusions are available as treatments. Diagnosis of acquired aplastic anemia involves blood tests to assess blood cell counts, bone marrow biopsy to determine the condition of the bone marrow, and ruling out other potential causes of bone marrow failure. Treatment options for acquired aplastic anemia depend on the severity of the disease. They may include blood transfusions to manage low blood cell counts, immunosuppressive therapy to suppress the immune system and allow the bone marrow to recover, or hematopoietic stem cell transplantation (HSCT) to replace damaged bone marrow with healthy stem cells from a compatible donor. 

Acquired aplastic anemia can potentially be treated with immunotherapy, which is a promising approach. Immunosuppressive therapies, such as anti-thymocyte globulin (ATG) and cyclosporine, suppress the immune system and halt bone marrow attacks. Newer immunotherapeutic approaches, such as targeted monoclonal antibodies and immune modulators, are being explored in clinical trials and may shape the future of acquired aplastic anemia treatment. In certain instances of AAA, bone marrow transplantation or HSCT may be a viable option. The market for acquired aplastic anemia includes advancements in HSCT techniques, donor selection, and post-transplant care to improve outcomes and expand the availability of transplantation options.

FutureWise Market Research has published a report that provides an insightful analysis of Acquired Aplastic Anemia Market trends affecting overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes the stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, Acquired Aplastic Anemia Market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition to providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organization to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.
  •  Bayer AG
  •  Novartis AG
  •  Pfizer Inc.
  •  Ligand Pharmceuticals Incorporated
  •  Genezyme Corporation (Sanofi)
  •  Mylan N.V.
  •  Biogen
  •  Otsuka Pharmaceutical Co. Ltd.
  •  Regen Biopharma Inc.
  •  BiolinRx

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by the key players in the acquired aplastic anemia market:

  • In June 2021, Novo Nordisk A/S and Heartseed Inc. have partnered to create and promote HS-001, a cell therapy that utilizes purified cardiomyocytes derived from pluripotent stem cells to combat heart failure. The therapy will undergo a clinical trial in Japan to confirm its safety and effectiveness, and has been approved by Japan's Pharmaceutical and Medical Devices Agency for the trial.

The development of advanced treatment options and therapeutic approaches has significantly improved outcomes for individuals with acquired aplastic anemia. It includes immunosuppressive therapies, targeted monoclonal antibodies, and hematopoietic stem cell transplantation. The availability of more effective and tailored treatment options drives market growth. While acquired aplastic anemia is a rare condition, its prevalence is increasing, which may be attributed to improved diagnostic techniques, increased awareness among healthcare professionals, and a better understanding of the disease. The number of diagnosed cases increases the demand for effective treatments and therapies. Ongoing research and development efforts contribute to the drivers of the acquired aplastic anemia market. Scientists and researchers continually explore new treatment modalities, including gene therapies and immunomodulatory drugs. These advancements aim to enhance the efficacy and safety of treatments, providing new options for patients and driving market growth. Novartis AG's romiplostim (Nplate) is a thrombopoietin receptor agonist approved for treating thrombocytopenia in people with AAA. Romiplostim is effective in increasing platelet counts in people with AAA and has been shown to improve quality of life hence responsible for market growth.

However, acquired aplastic anemia treatment can be expensive, particularly in situations requiring cutting-edge procedures like hematopoietic stem cell transplantation (HSCT). High treatment costs result from complicated procedures, lengthy hospital stays, and substantial supporting care required for HSCT. Advanced treatment alternatives' accessibility and price may hinder market expansion. There are difficulties with hematopoietic stem cell transplantation (HSCT), which is recommended as a curative therapy for severe acquired aplastic anemia. The complexity of selecting appropriate donors, handling problems associated with transplantation, and guaranteeing long-term graft survival may restrict HSCT as a therapy option for all patients. These difficulties can affect the market by reducing HSCT's accessibility and application hence limiting the market growth.

By Type

  •  Moderate Aplastic Anemia
  •  Severe Aplastic Anemia
  •  Very Severe Aplastic Anemia

By Diagnosis

  •  Bone Marrow Biopsy
  •  X-Rays
  •  Computed Tomography (CT) Scans

By Treatment

  •  Bone Marrow Transplantation
  •  Immunosuppressive Therapies

By End User

  •  Hospitals and clinics
  •  Research Centers

By Region

  •  North America
  •  Europe
  •  Asia-Pacific
  •  Latin America
  •  Middle East and Africa

This market research report also emphasizes factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America is the largest market for acquired aplastic anemia, accounting for the highest global market share. The expansion of the market in North America is being propelled by the rising incidence of AAA in the region, as well as the growing awareness about the ailment and the accessibility of cutting-edge therapies. The United States is North America's largest market for acquired aplastic anemia, followed by Canada. North America, particularly the United States, has higher healthcare spending than many other regions, allowing for more significant investment in medical advancements, access to state-of-the-art technologies, and advanced treatment options for aplastic anemia patients. Higher healthcare spending contributes to the market dominance in North America. 
  •  Tier 1 players- established companies in the market with a major market share
  •  Tier 2 players
  •  Emerging players which are growing rapidly
  •  New Entrants
  •  Growth prospects
  •  SWOT analysis
  •  Key trends
  •  Key data-points affecting market growth
  •  To provide with an exhaustive analysis on the Acquired Aplastic Anemia Market By Type, By Diagnosis, By Treatment, By End User and By Region.
  •  To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  •  To evaluate and forecast micro-markets and the overall market
  •  To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  •  To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  •  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization Mobility Care offered are free of charge with purchase of any license of the report
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Acquired Aplastic Anemia Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Acquired Aplastic Anemia Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Acquired Aplastic Anemia Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals and Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Acquired Aplastic Anemia Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Moderate Aplastic Anemia
        2. Severe Aplastic Anemia
        3. Very Severe Aplastic Anemia

  • 8.   Global Acquired Aplastic Anemia Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Bone Marrow Biopsy
        2. X-Rays
        3. Computed Tomography (CT) Scans

  • 9.   Global Acquired Aplastic Anemia Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Bone Marrow Transplantation
        2. Immunosuppressive Therapies

  • 10.   Global Acquired Aplastic Anemia Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospitals and clinics
        2. Research Centers

  • 11.   North America Acquired Aplastic Anemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Acquired Aplastic Anemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Acquired Aplastic Anemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Acquired Aplastic Anemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Bayer AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Novartis AG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Pfizer Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Ligand Pharmceuticals Incorporated
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Genezyme Corporation (Sanofi)
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Mylan N.V.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Biogen
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Otsuka Pharmaceutical Co. Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Regen Biopharma Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. BiolinRx
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11